Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology

Next Previous
Trial Profile

A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Flortaucipir-F-18 (Primary)
  • Indications Alzheimer's disease
  • Focus Diagnostic use; Registrational
  • Sponsors Avid Radiopharmaceuticals

    • Most Recent Events

    • 04 Aug 2022 Results of retrospective analysis of the AV-1451-A16 (n=60) presented at the Alzheimer's Association International Conference 2022
    • 28 May 2020 Results published in the U.S. Food and Drug Administration Media Release.
    • 28 May 2020 According to an U.S. Food and Drug Administration media release, it has approved Tauvid (flortaucipir F18) for intravenous injection under Priority Review. It is the first drug used to help image a distinctive characteristic of Alzheimer's disease in the brain called tau pathology. The safety and effectiveness of Tauvid imaging was evaluated in two clinical studies, Study 1 (NCT02516046) and Study 2 (NCT03901092).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top